Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Werewolf Therapeutics (HOWL) Enterprise Value (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Enterprise Value for 5 consecutive years, with -$65.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 46.5% to -$65.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$65.7 million, a 46.5% increase, with the full-year FY2024 number at -$111.0 million, up 17.38% from a year prior.
  • Enterprise Value was -$65.7 million for Q3 2025 at Werewolf Therapeutics, up from -$77.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$65.7 million in Q3 2025 to a low of -$183.2 million in Q2 2021.
  • A 5-year average of -$128.9 million and a median of -$135.3 million in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: tumbled 69.87% in 2022, then soared 46.5% in 2025.
  • Werewolf Therapeutics' Enterprise Value stood at -$157.5 million in 2021, then increased by 17.91% to -$129.3 million in 2022, then decreased by 3.89% to -$134.3 million in 2023, then grew by 17.38% to -$111.0 million in 2024, then skyrocketed by 40.8% to -$65.7 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Enterprise Value are -$65.7 million (Q3 2025), -$77.6 million (Q2 2025), and -$92.0 million (Q1 2025).